68 filings
Page 2 of 4
8-K
e483e 2nn
23 Jan 23
Departure of Directors or Certain Officers
7:31am
8-K
r1fcskosxba
8 Nov 22
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
7:07am
8-K
1mnxbu8 z30nt19
3 Nov 22
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:08am
8-K
m2o2v a77
7 Sep 22
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors
7:03am
8-K
e11gol fsk
4 Aug 22
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:03am
8-K
tqdye65
15 Jul 22
Entry into a Material Definitive Agreement
5:22pm
8-K
bi0os2f se8560vd5
12 Jul 22
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
4:00pm
8-K
mlzdhc7fjj 996hjs
27 Jun 22
Submission of Matters to a Vote of Security Holders
4:10pm
8-K
gni aq95s4q
5 May 22
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
7:06am
8-K
t28xvbpjtc
12 Apr 22
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
4:14pm
8-K
1b6lrk8y ll01hp9y5x
1 Mar 22
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
7:00am
8-K
ybn4mj3
5 Jan 22
Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team
7:14am
8-K
r141svj4bbnyxyeub
8 Nov 21
Regulation FD Disclosure
5:02pm
8-K
pk9qqtd
4 Nov 21
Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
7:00am
8-K
og7miwjgb lzx
26 Oct 21
Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration
8:58am
8-K
5b49m 7mt3
14 Oct 21
Entry into a Material Definitive Agreement
12:00am
8-K
z6r4 e01mldi
7 Oct 21
Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial
4:14pm
8-K
g1o8p003u3
5 Aug 21
Bicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7:00am
8-K
cwk5ifljdns5wdw
13 Jul 21
Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics
7:54am
8-K
z1s jh8grwxw5eds
28 Jun 21
Submission of Matters to a Vote of Security Holders
4:43pm